D. Simper et al., INDIRECT EVIDENCE FOR STIMULATION OF NITRIC-OXIDE RELEASE BY TUMOR-NECROSIS-FACTOR-ALPHA IN HUMAN VEINS IN-VIVO, Cardiovascular Research, 30(6), 1995, pp. 960-964
Objectives: The detrimental haemodynamic changes observed in septicaem
ia are generalised vasodilation, arterial hypotension, and hyporespons
iveness to vasopressor compounds, all of which could be explained by t
he release of an endogenous vasodilator. Experimental and clinical evi
dence suggests that tumour necrosis factor-alpha (TNF) induces the exp
ression of vascular nitric oxide (NO) synthase within hours and that N
O released from smooth muscle cells could be involved in the pathogene
sis of septic shock. The aim of this study was to investigate the role
of NO in the vascular effects of TNF. Methods: Using the dorsal hand
vein compliance technique, the effect of the NO synthase inhibitor L-N
-G-monomethyl-arginine (L-NMMA) on alpha(1)-adrenergic responsiveness
(phenylephrine 1.25-8000 ng/min) was studied after prolonged local ven
ous infusion of TNF (8.7 mu g in 5 h) in 9 volunteers and in 6 volunte
ers without previous cytokine exposure. Results: Mean (+/-s.e.) maximu
m phenylephrine constriction (E(max)) was 73 +/- 6% and log dose-rates
exerting 50% of E(max) (log ED(50)) were 3.2 +/- 0.09 (geometric mean
: 1535 ng/min). Local co-administration of L-NMMA at a dose sufficient
ly high to block NO formation (3.4 mu mol/min) increased venous sensit
ivity to phenylephrine threefold (log ED(50) 2.8 +/- 0.1, P < 0.015; g
eometric mean: 574 ng/min) whereas E(max) was similar (73 +/- 5%). In
the controls the phenylephrine dose-response relationship remained una
ffected by simultaneous administration of L-NMMA. Conclusions: As no b
asal release of NO occurs in hand veins without previous exposure to T
NF these results provide direct evidence for induction of NO formation
in the human vasculature and consecutive resistance to alpha-adrenerg
ic venoconstriction. NO might, therefore, be a key mediator of haemody
namic impairment in humans under conditions with known elevations of c
irculating TNF, such as a septic shock.